SEC Tracker
Get the app

Omeros OMER

Omeros: signs a material agreement, takes on a new financial obligation and 2 other items

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract
Exhibit 99.1
Press release
  • Signs a material agreement (1.01)
  • Takes on a new financial obligation (2.03)
  • Makes a Regulation FD disclosure (7.01)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Omeros files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
  2. XOMA Royalty XOMA public float $168M, Jun 30, 2025
  3. Crescent Biopharma CBIO public float $177M, Jun 30, 2025
  4. Forte Biosciences FBRX public float $157M, Jun 30, 2025
  5. Neurogene NGNE public float $146M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.